UA83484C2 - Способ лечения рака молочной железы комбинацией производного рапамицина и ингибитора ароматазы - летрозола, фармацевтическая композиция - Google Patents

Способ лечения рака молочной железы комбинацией производного рапамицина и ингибитора ароматазы - летрозола, фармацевтическая композиция Download PDF

Info

Publication number
UA83484C2
UA83484C2 UAA200509283A UA2005009283A UA83484C2 UA 83484 C2 UA83484 C2 UA 83484C2 UA A200509283 A UAA200509283 A UA A200509283A UA 2005009283 A UA2005009283 A UA 2005009283A UA 83484 C2 UA83484 C2 UA 83484C2
Authority
UA
Ukraine
Prior art keywords
aai
aza
miyiza
mkr
aaia
Prior art date
Application number
UAA200509283A
Other languages
English (en)
Ukrainian (uk)
Inventor
Меттью Л. Шерман
мл. Гиббонс Джеймс Дж.
Марк Бергер
Роберт Т. Магвайр
Роберт Фридман
Original Assignee
Уайт
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32962706&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA83484(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Уайт filed Critical Уайт
Publication of UA83484C2 publication Critical patent/UA83484C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
UAA200509283A 2003-03-05 2004-01-03 Способ лечения рака молочной железы комбинацией производного рапамицина и ингибитора ароматазы - летрозола, фармацевтическая композиция UA83484C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45228903P 2003-03-05 2003-03-05
PCT/US2004/006354 WO2004078133A2 (en) 2003-03-05 2004-03-01 Antineoplastic combinations comprising a rapamycin derivative and an aromatase inhibitor

Publications (1)

Publication Number Publication Date
UA83484C2 true UA83484C2 (ru) 2008-07-25

Family

ID=32962706

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200509283A UA83484C2 (ru) 2003-03-05 2004-01-03 Способ лечения рака молочной железы комбинацией производного рапамицина и ингибитора ароматазы - летрозола, фармацевтическая композиция

Country Status (20)

Country Link
US (1) US20040176339A1 (ru)
EP (1) EP1603561A2 (ru)
JP (1) JP2006519862A (ru)
KR (1) KR20050109965A (ru)
CN (1) CN1756549A (ru)
AR (1) AR043403A1 (ru)
AU (1) AU2004218439A1 (ru)
BR (1) BRPI0408024A (ru)
CA (1) CA2516353A1 (ru)
CR (1) CR7942A (ru)
EC (1) ECSP056001A (ru)
MX (1) MXPA05009246A (ru)
NI (1) NI200500148A (ru)
NO (1) NO20054133L (ru)
NZ (1) NZ542738A (ru)
RU (1) RU2355399C2 (ru)
TW (1) TW200529829A (ru)
UA (1) UA83484C2 (ru)
WO (1) WO2004078133A2 (ru)
ZA (1) ZA200508029B (ru)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI233359B (en) * 2001-04-06 2005-06-01 Wyeth Corp Pharmaceutical composition for treating neoplasm
US20020198137A1 (en) * 2001-06-01 2002-12-26 Wyeth Antineoplastic combinations
MXPA05013865A (es) * 2003-07-25 2006-02-28 Wyeth Corp Formulaciones liofilizadas de cci-779.
DK1701698T3 (da) * 2004-01-08 2008-05-05 Wyeth Corp Direkte komprimerbart farmaceutisk præparat til oral indgivelse af CCI-779
AR047988A1 (es) * 2004-03-11 2006-03-15 Wyeth Corp Combinaciones antineoplásicas de cci-779 y rituximab
WO2006050461A1 (en) * 2004-10-28 2006-05-11 Wyeth Use of an mtor inhibitor in treatment of uterine leiomyoma
CN108421044A (zh) 2005-02-03 2018-08-21 综合医院公司 治疗吉非替尼耐药性癌症的方法
BRPI0618042A2 (pt) 2005-11-04 2011-08-16 Wyeth Corp usos de uma rapamicina e de uma herceptina, produto, pacote farmacêutico, e, composição farmacêutica
EP2275103B1 (en) * 2005-11-21 2014-04-23 Novartis AG mTOR inhibitors in the treatment of endocrine tumors
DE102006008074B4 (de) * 2006-02-22 2013-08-14 RUHR-UNIVERSITäT BOCHUM Behandlung von Krebs mit Geruchsrezeptor-Liganden
DE102006011507A1 (de) * 2006-03-14 2007-09-20 Lts Lohmann Therapie-Systeme Ag Wirkstoffbeladene Nanopartikel auf Basis hydrophiler Proteine
RU2010104916A (ru) * 2006-08-16 2011-08-20 Михаил В. Благосклонный (US) Способ профилактики и лечения возрастных заболеваний
US8998846B2 (en) 2006-11-20 2015-04-07 Lutonix, Inc. Drug releasing coatings for balloon catheters
US9700704B2 (en) 2006-11-20 2017-07-11 Lutonix, Inc. Drug releasing coatings for balloon catheters
US8414910B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US8414526B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids
US8425459B2 (en) 2006-11-20 2013-04-23 Lutonix, Inc. Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent
US8414525B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US20080175887A1 (en) 2006-11-20 2008-07-24 Lixiao Wang Treatment of Asthma and Chronic Obstructive Pulmonary Disease With Anti-proliferate and Anti-inflammatory Drugs
US20080276935A1 (en) 2006-11-20 2008-11-13 Lixiao Wang Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs
US9737640B2 (en) 2006-11-20 2017-08-22 Lutonix, Inc. Drug releasing coatings for medical devices
TW200901989A (en) * 2007-04-10 2009-01-16 Wyeth Corp Anti-tumor activity of CCI-779 in papillary renal cell cancer
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
CN102641270A (zh) 2008-06-17 2012-08-22 惠氏有限责任公司 含有hki-272和长春瑞滨的抗肿瘤组合
US8669273B2 (en) 2008-08-04 2014-03-11 Wyeth Llc Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine
WO2010024898A2 (en) 2008-08-29 2010-03-04 Lutonix, Inc. Methods and apparatuses for coating balloon catheters
WO2010056574A1 (en) * 2008-11-11 2010-05-20 Eli Lilly And Company P70 s6 kinase inhibitor and mtor inhibitor combination therapy
IL264349B2 (en) 2009-04-06 2024-01-01 Wyeth Llc Regimen comprising neratinib for the treatment of cancer
KR20130128018A (ko) * 2009-04-10 2013-11-25 하이얀 치 새로운 노화 방지 물질 및 그 확인 방법
TR201816243T4 (tr) 2011-01-31 2018-11-21 Lucolas M D Ltd Aromataz inhibitörlerinin ve antioksidanların kombinasyonları.
US9682066B2 (en) * 2012-12-04 2017-06-20 University Of Cincinnati Methods of treating primary brain tumors by administering letrozole
WO2015014284A1 (zh) * 2013-07-31 2015-02-05 北京盛诺基医药科技有限公司 一种乳腺癌的治疗方法
JP6529012B2 (ja) 2013-10-08 2019-06-12 エイアイ・セラピューティクス・インコーポレーテッド リンパ脈管筋腫症の処置のためのラパマイシン
NZ724756A (en) 2014-04-04 2023-07-28 Ai Therapeutics Inc An inhalable rapamycin formulation for treating age-related conditions
AU2015330905B2 (en) 2014-10-07 2021-02-25 AI Therapeutics, Inc. An inhalable rapamycin formulation for the treatment of pulmonary hypertension

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5A (en) * 1836-08-10 Thomas Blanchard Machine for mortising solid wooden shells of ships' tackle-blocks
US6A (en) * 1836-08-10 Thomas Blanchard Machine for forming end pieces of plank blocks for ships
ZA737247B (en) * 1972-09-29 1975-04-30 Ayerst Mckenna & Harrison Rapamycin and process of preparation
US3993749A (en) * 1974-04-12 1976-11-23 Ayerst Mckenna And Harrison Ltd. Rapamycin and process of preparation
US4885171A (en) * 1978-11-03 1989-12-05 American Home Products Corporation Use of rapamycin in treatment of certain tumors
US5206018A (en) * 1978-11-03 1993-04-27 Ayerst, Mckenna & Harrison, Inc. Use of rapamycin in treatment of tumors
US5066493A (en) * 1978-11-03 1991-11-19 American Home Products Corporation Rapamycin in treatment of tumors
US4401653A (en) * 1981-03-09 1983-08-30 Ayerst, Mckenna & Harrison Inc. Combination of rapamycin and picibanil for the treatment of tumors
US5100899A (en) * 1989-06-06 1992-03-31 Roy Calne Methods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof
US5078999A (en) * 1991-02-22 1992-01-07 American Home Products Corporation Method of treating systemic lupus erythematosus
US5080899A (en) * 1991-02-22 1992-01-14 American Home Products Corporation Method of treating pulmonary inflammation
US5321009A (en) * 1991-04-03 1994-06-14 American Home Products Corporation Method of treating diabetes
IL102414A (en) * 1991-07-25 1996-08-04 Univ Louisville Res Found Medicinal preparations for the treatment of ocular inflammation, containing rapamycin
US5286730A (en) * 1991-09-17 1994-02-15 American Home Products Corporation Method of treating immunoinflammatory disease
US5286731A (en) * 1991-09-17 1994-02-15 American Home Products Corporation Method of treating immunoinflammatory bowel disease
US5516781A (en) * 1992-01-09 1996-05-14 American Home Products Corporation Method of treating restenosis with rapamycin
US5288711A (en) * 1992-04-28 1994-02-22 American Home Products Corporation Method of treating hyperproliferative vascular disease
US5302584A (en) * 1992-10-13 1994-04-12 American Home Products Corporation Carbamates of rapamycin
US5362718A (en) * 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
US5561138A (en) * 1994-12-13 1996-10-01 American Home Products Corporation Method of treating anemia
US5496832A (en) * 1995-03-09 1996-03-05 American Home Products Corporation Method of treating cardiac inflammatory disease
US6002008A (en) * 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
US6277983B1 (en) * 2000-09-27 2001-08-21 American Home Products Corporation Regioselective synthesis of rapamycin derivatives
ES2228932T3 (es) * 2000-08-11 2005-04-16 Wyeth Procedimiento de tratamiento del carcinoma positivo de estrogenos.
TWI286074B (en) * 2000-11-15 2007-09-01 Wyeth Corp Pharmaceutical composition containing CCI-779 as an antineoplastic agent
LT2762140T (lt) * 2001-02-19 2017-06-26 Novartis Ag Solidinių smegenų navikų gydymas rapamicino dariniu
TWI296196B (en) * 2001-04-06 2008-05-01 Wyeth Corp Antineoplastic combinations
TWI233359B (en) * 2001-04-06 2005-06-01 Wyeth Corp Pharmaceutical composition for treating neoplasm
CN1309421C (zh) * 2001-04-06 2007-04-11 惠氏公司 诸如雷帕霉素和吉西他滨或氟尿嘧啶的抗肿瘤联合
US20030008923A1 (en) * 2001-06-01 2003-01-09 Wyeth Antineoplastic combinations
WO2002098416A2 (en) * 2001-06-01 2002-12-12 Wyeth Antineoplastic combinations
UA77200C2 (en) * 2001-08-07 2006-11-15 Wyeth Corp Antineoplastic combination of cci-779 and bkb-569

Also Published As

Publication number Publication date
NI200500148A (es) 2006-03-30
EP1603561A2 (en) 2005-12-14
NZ542738A (en) 2009-02-28
CN1756549A (zh) 2006-04-05
NO20054133L (no) 2005-10-03
CR7942A (es) 2006-02-07
AU2004218439A1 (en) 2004-09-16
WO2004078133A3 (en) 2004-11-11
MXPA05009246A (es) 2005-10-19
CA2516353A1 (en) 2004-09-16
ZA200508029B (en) 2007-04-25
WO2004078133A2 (en) 2004-09-16
RU2005130767A (ru) 2006-02-10
TW200529829A (en) 2005-09-16
RU2355399C2 (ru) 2009-05-20
US20040176339A1 (en) 2004-09-09
BRPI0408024A (pt) 2006-02-14
KR20050109965A (ko) 2005-11-22
AR043403A1 (es) 2005-07-27
WO2004078133A8 (en) 2005-09-01
ECSP056001A (es) 2006-01-27
NO20054133D0 (no) 2005-09-06
JP2006519862A (ja) 2006-08-31

Similar Documents

Publication Publication Date Title
CN309147373S (zh) 耳机（鱼玄机花影）
CN309075927S (zh) 耳机（x001）
CN309154592S (zh) 耳机（hkd03）
CN309329233S (zh) 耳机（OWS pro）
CN309135773S (zh) 磁吸充电宝（x-wxc-137）
CN309318883S (zh) 耳机（xzx20240926001-1）
CN309196684S (zh) 蓝牙耳机（nox02）
CN309154546S (zh) 蓝牙耳机（ge10）
CN309187952S (zh) 蓝牙耳机（ge09）
CN309192320S (zh) 耳机壳（透明防摔磁吸弹跳开关-gwh）
CN309239437S (zh) 无线耳机接收器（y001）
CN309875123S (zh) 智能通话手表（x3）
CN309099369S (zh) 无线耳机（x2）
CN309196658S (zh) 耳机（x02）
CN309313799S (zh) 耳机（耳环型）
CN309099368S (zh) 无线耳机（x1）
CN309341508S (zh) 耳机（im03）
CN309171723S (zh) 耳机（岚）
CN309130827S (zh) 耳机（bt070）
CN309753649S (zh) 蓝牙耳机（s9）
CN309224842S (zh) 蓝牙耳机及耳机盒（btw92se）
CN309793520S (zh) 磁吸手机支架（带蓝牙音箱）
CN309659647S (zh) 麦克风监听器（腰包d1）
CN309232604S (zh) 蓝牙耳机（m51）
CN309075911S (zh) 耳机（v10三角）